NCT03664687 2026-02-09
REaCT-ZOL
Ottawa Hospital Research Institute
Phase 4 Completed
Clinical Trials
50 trialsNCT00365105 2024-09-20
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00295646 2024-03-15
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
Austrian Breast & Colorectal Cancer Study Group
Phase 3 Completed
NCT00525759 2023-11-24
ANZAC
Sheffield Teaching Hospitals NHS Foundation Trust
Phase 2 Completed
NCT00172029 2023-08-18
Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid
Novartis
Phase 4 Completed
NCT00556374 2023-07-27
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Amgen
Phase 3 Completed
NCT00321464 2022-11-08
A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.
Amgen
Phase 3 Completed
NCT00566618 2022-02-25
Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00127205 2021-07-02
S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.
SWOG Cancer Research Network
Phase 3 Completed
NCT00424983 2020-12-21
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
Novartis
Phase 1 Completed
NCT02721433 2020-12-02
REaCT-BTA
Ottawa Hospital Research Institute
Phase 4 Completed
NCT00295867 2020-05-12
Zoledronate in Treating Bone Marrow Micrometastases in Women With Stage I, Stage II, or Stage III Breast Cancer
University of California, San Francisco
Phase 2 Completed
NCT01099436 2020-01-21
NEO-ZOTAC
Borstkanker Onderzoek Groep
Phase 3 Completed
NCT00213980 2019-11-27
Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer
University of Wisconsin, Madison
Phase 2 Completed
NCT00436917 2019-09-11
Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer
Mayo Clinic
Phase NA Completed
NCT01367288 2019-05-28
NEOZOL
Hospices Civils de Lyon
Phase 2 Completed
NCT00869206 2018-11-07
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT01194440 2018-09-12
Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00399802 2018-08-16
A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT01907880 2017-07-07
ER11-03
Ottawa Hospital Research Institute
Phase 4 Completed
NCT01472146 2017-05-09
ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer
Instituto Nacional de Cancer, Brazil
Phase 2 Completed
NCT00247650 2017-03-01
Comparison Study of Letrozole Alone or Letrozole With Zoledronic Acid in Early Breast Cancer, Neoadjuvant Therapy
Novartis
Phase 2 Completed
NCT00434447 2017-02-27
Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases
Novartis
Phase 4 Completed
NCT00434317 2017-02-23
Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases
Novartis
Phase 4 Completed
NCT00334139 2017-02-07
Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
Novartis
Phase 4 Completed
NCT00107263 2016-12-06
Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00022087 2016-07-19
Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00903162 2016-04-18
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00582920 2015-12-24
Investigation of Changes in Bone Scan Imaging Before and After Intravenous Bisphosphonate Therapy for Osseous Metastases From Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00202059 2015-12-16
Effects of Zometa and Physical Activity on Bone Density in Women Receiving Chemotherapy for Breast Cancer
HealthPartners Institute
Phase 3 Completed
NCT00375505 2015-09-07
The Safety and Efficacy of Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss
Novartis
Phase 3 Completed
NCT00512993 2015-03-05
NATAN
GBG Forschungs GmbH
Phase 3 Completed
NCT00320710 2014-08-22
Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer
Novartis
Phase 3 Completed
NCT01129336 2014-05-20
MACS1295
Novartis
Phase 4 Completed
NCT00712985 2014-04-24
CTIBL
Milton S. Hershey Medical Center
Phase 3 Completed
NCT00050011 2014-03-21
Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
Novartis
Phase 3 Completed
NCT00049452 2014-01-06
Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00242203 2013-08-13
Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer
Washington University School of Medicine
Phase 2 Completed
NCT00558272 2013-05-27
Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease
AstraZeneca
Phase 2 Completed
NCT00060138 2013-05-15
Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases
Chugai Pharmaceutical
Phase 1/2 Completed
NCT00114270 2013-03-26
Letrozole With or Without Zoledronate in Treating Healthy Postmenopausal Women With High Breast Density
National Cancer Institute (NCI)
Phase NA Completed
NCT00171340 2012-04-16
Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.
Novartis
Phase 3 Completed
NCT00171314 2012-04-11
The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer
Novartis
Phase 3 Completed
NCT00375427 2012-04-11
Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions
Novartis
Phase 3 Completed
NCT00029224 2012-02-01
Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
Novartis
Phase 4 Completed
NCT00760370 2011-12-07
Comparison of Zometa Retention and Effect in Multiple Myeloma and Breast Cancer
Vejle Hospital
Phase 2 Completed
NCT00332709 2011-11-16
Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
Novartis
Phase 3 Completed
NCT00376740 2011-08-23
Effectiveness of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving Letrozole
Soroka University Medical Center
Phase 3 Completed
NCT00264420 2010-12-21
Safety and Efficacy Study of Concomitant Radiotherapy and Zoledronic Acid for Bone Metastases Palliation
The Cleveland Clinic
Phase 1 Completed
NCT00524849 2010-09-14
Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis
Fudan University
Phase 2/3 Completed